Amaç: Duyarlılık açısından sınırlı olan immünolojik yöntem-ler kullanılarak özellikle normal dokulardaki P-glikoprotein ekpresyonunun belirlenmesi sorun oluşturmaktadır. Bu çalış-mada hematolojik malignansi tanısı almış ve tedaviye yanıt vermeyen hastalarda P-glikoprotein ve CD34 ekpresyonunun değerlendirilmesi için, P-glikoprotein and CD34 ekpresyonunun akım sitometri ile belirlenmesini amaçladık.
INTRODUCTION
Considerable progress has been made in the therapy of acute lymphocytic leukemia (ALL) and despite complete remission exceeding 90% in contemporary treatment series, overall survival rates of adults with ALL are within the range of 30-40% [1] [2] [3] . Similarly, there has been great progress in the treatment of acute myeloid leukemia (AML), and 70 to 80% of newly diagnosed patients have achieved complete remission. However, often associated with multiple drug resistance (MDR), relapse occurs in more than 50% of the patients [4] . P-glycoprotein (P-gp) expression, which causes the formation of MDR in the cell, can be assessed by various laboratory methods [5] . Determination expression of P-gp is especially problematic for normal tissues since immunological methods are limited in terms of sensitivity. The use of western blot methodologies which require large numbers of tumor cells to obtain sufficient protein for a reliable result is insufficient. A more focused approach using flow cytometric methodologies offers potential for the solution to this problem. Flow cytometry is a method that can be applied quickly and easily before and after chemotherapy in hematologic malignancies [6] [7] [8] [9] [10] . P-gp is believed to function as an energy-dependent drug efflux pump for various lipophilic xenobiotics, resulting in reduced intracellular accumulation [11] . CD34 is a member of the singlepass transmembrane sialomucin protein family and a cell-cell adhesion factor expressed in some cell types; and recent reports have demonstrated that CD34 can alter the cell adhesion, migration, and engraftment potential of hematopoietic progenitor cells in bone marrow (BM) niche [12] [13] [14] [15] . During the differentiation of leukemia cells, while the expression of P-gp decreases, expression of CD34 increases in AML malignant cells [16] [17] [18] . However, whether CD34 levels correlate with the expression or function of P-gp remains unclear [19] . Therefore, this study was designed to determine the expression of P-gp and CD34 by flow cytometry, and to find out the expression of P-gp and CD34 with unresponsive treatment in patients with AML and ALL.
METHODS

Participants
The study group consisted of 50 patients who were present at Erciyes University, Mehmet Kemal Dedeman Hematology-Oncology Hospital. The patients were diagnosed with AML (16 females, 14 males) and diagnosed with ALL (10 females, 10 males). Twenty healthy controls (10 females, 10 males) were also included in the study. After they were asked for their consent, BM samples were obtained from 30 patients, and blood samples were obtained from both patients and healthy controls group. The study was approved by Ethics Committee of Erciyes University Faculty of Medicine (Decision number: 2010/65, Decision Date: 08.07.2010). The study was carried out in accordance with the principles of the Helsinki Convention on Human Rights [20] .
Preparation of Samples
Peripheral blood samples were collected in glass tubes (sample tubes with acidum citrose-dextrose solution A; Becton Dickinson, San Jose, CA, USA); and leukemic peripheral blood mononuclear cells were isolated by density gradient separation (FicollHypaque specific density 1.077; NycoMed, Oslo, Norway) immediately after sampling.
Cells were frozen without delay and stored frozen in liquid nitrogen. BM aspirate samples were washed once in pre-warmed phosphate buffered saline. Lymphocytes, monocytes, and granulocytes must exist in the cell environment to make optimal analysis possible by flow cytometry. Therefore, the erythrocytes were removed from peripheral blood and BM samples. To achieve this, 1.5 mL BD cell lysis solution was added to each of the mixture in the tubes Falcon; and mixtures were incubated in darkness for 8 minutes after they were quickly vortexed. Each tube was centrifuged for 5 minutes at 1500 rpm after the incubation for 8 minutes. Supernatant was discarded after centrifugation. 2 mL of BD cell wash solution was added to pellet on the bottom of the tubes and tubes were centrifuged for 5 minutes at 1500 rpm for the second time. Supernatant was discarded after centrifugation. Pellets were vortexed quickly, and 500 μL of BD cell washing solution was added into the tubes [21] . [21] .
Statistical analysis
Statistical analysis were performed using statistics programs with SPSS software version 15.0. Statistical comparisons were performed using chi-square exact method. Data were expressed as mean ± SD for continuous variables. Statistical significance was set as p<0.05.
RESULTS
The control group consisted of 20 individuals of without hematologic malignancy (10 females, 10 males, mean age 48.2±16.5 years 
Flow cytometric analysis of CD34 and P-gp expression
Expression of P-gp and CD34 was not observed in the samples of control group. Flow cytometric images of one subject in the control group are shown in Figure 1 .
When we analyzed the BM of AML group using flow cytometry, we observed strong expression of P-gp and CD34 in 6 of 30 (20%) AML patients. P-gp and CD34 expression was not observed in 24 of 30 (80%) AML patients (Table 1) . Flow cytometric images of one subject in the AML group are shown in Figure 2 . When we analyzed BM of ALL group using flow cytometry, we observed strong expression of P-gp and CD34 in 5 of 20 (25%) ALL patients. We found that there was strong expression of P-gp but there was not CD34 expression in one of 20 (5%) ALL patients. P-gp and CD34 expression was not observed in 14 of 20 (70%) ALL group (Table 1) . Flow cytometric images of one subject in the ALL group are shown in Figure 3 . The distribution of P-gp and CD34 expression by gender in AML and ALL groups P-gp expression was observed 12.5% in females and 28.6% in males of AML patients. P-gp expression was observed 20% in females and 40% in males of ALL patients. CD34 expression was observed 12.5% in females and 28.6% in males of AML patients. CD34 expression was observed 20% in females and 30% in males of ALL patients. There was not any significant difference between male and female expressions in terms of P-gp and CD34 (Table 2) .
AML Group P-gp Expression ALL Group P-gp Expression
Gender (n) (n) P-gp (+) (n) P-gp (-) Gender (n) (n) P-gp (+) (n) P-gp (-)
Female (16) (2) 
CD34 Expression CD34 Expression
DISCUSSION
Our results provide evidence of MDR as shown by positive expression of P-gp and CD34 in patients with AML and ALL. On the other hand, very low P-gp expression is observed in stem cells of normal hematopoiesis, which is consistent with previous studies [22, 23] .
Many methods using the determination of P- the functional levels [24] [25] [26] . However, as a result of research conducted in several centers, Chevillard et al. recommended the use of flow cytometry for analyses of MDR in protein levels and the use of real time polymerase chain reaction method in the mRNA levels [27] . In our study, MDR-1 expressions were measured with flow cytometry using 17F9 specific monoclonal antibody for P-gp membrane surface epitopes. Both the threshold value of P-gp and the functional status of the synthesized P-gp play a role in the appearance of clinical resistance phenotype [28] . Therefore, it is necessary to determine the threshold value for P-gp positivity in the method used in the determination of P-gp. In the present study, 102 and a higher level of fluorescence intensity was evaluated as positive on forward scattered light-side scattered light screen in flow cytometry.
We found that CD34 and P-gp expression levels are consistent with each other in patients with AML. We also showed that positive expression of P-gp and CD34 in 6 (20%) of 30 patients with AML and in 5 (25%) of 20 patients with ALL receiving chemotherapy.
The positive expressions of P-gp were evaluated for the presence of drug resistance. The increase of P-gp expression accelerates the elimination of drugs which are used in the treatment of ALL and AML. Thus, cancer cells are protected from the cytotoxic effects of chemotherapeutic drugs. Kuwazuru et al. showed that 9 of 17 patients with AML and 4 of 11 patients with ALL had P-gp positive results at the initial presentation, and most P-gp positive patients did not respond to chemotherapy [29] . Pall et al. observed a significant correlation between CD34 expression and activity of P170 in AML patients. Senent et al. [30] conducted a study in patients with 82 AML by immunocytochemical method using the monoclonal antibody C219, and showed that CD34 expression were positive in 8 of P-gp positive 13 cases (62%). The researchers emphasized that Pglycoprotein expression is a reliable marker of patients first diagnosed with AML. Consistent with our study, Gruber et al. [31] stated that expression of the MDR-1 gene could be an important factor contributing to drug resistance in acute leukemia. Similarly, Boekhorst et al. [32] reported that expression of P-170 encoded by the MDR-1 should be related to the MDR. In the present study, we also found that 24 patients were seen in the remission process. P-gp and CD34 expressions were not observed in individuals entering remission process and controls group. These findings show that the treatments were successful. El-Ghaffar et al. [33] conducted a study on patients with acute leukemia (14 AML cases and 6 ALL cases); and showed that the functional activity of MDR-1 P-gp was 71.4% in AML and 33.3% in ALL patients compared with 16.6% in normal lymphocytes. They suggested that P-gp/170 is expressed to a higher degree in leukemic cells and this is greater in relapse when compared to de novo cases and more in AML than ALL blasts.
In light of these findins, the results suggest the expression of P-gp is closely related to clinical drug resistance in acute leukemia. We also investigated the expression of P-170 encoded by the MDR-1 with flow cytometry; and we observed that P-gp was positive in patients with recurrence. The observation of MDR at a higher rate in ALL patients compared to patients with AML suggests that it may have occurred due to different morphological and phenotypic characteristics of ALL patients. There are several limitations for our study. Firstly, the small number of patients may be perceived as a limitation of the study. However, the major limitation of the study is that there was no way to evaluate the effect of individual chemotherapeutic agents that was used.
In conclusion, in terms of MDR, examination of patients diagnosed with hematologic malignancy especially in recurrent cases will shed light on chemotherapy resistance encountered in these patients. For measurement of MDR by flow cytometry, the most important advantages are the ones that make it possible to easily identify the cell clones of gated leukemic (blastic) and to make them specifically be analyzed in terms of P-gp. P-glycoprotein expression can be measured quickly by flow cytometry; and this may pave the way to more rapid implementation of alternative treatment regimens in especially in recurrent cases.
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